Proteomics for development of vaccine

J Proteomics. 2011 Nov 18;74(12):2596-616. doi: 10.1016/j.jprot.2011.01.019. Epub 2011 Feb 20.

Abstract

The success of genome projects has provided us with a vast amount of information on genes of many pathogenic species and has raised hopes for rapid progress in combating infectious diseases, both by construction of new effective vaccines and by creating a new generation of therapeutic drugs. Proteomics, a strategy complementary to the genomic-based approach, when combined with immunomics (looking for immunogenic proteins) and vaccinomics (characterization of host response to immunization), delivers valuable information on pathogen-host cell interaction. It also speeds the identification and detailed characterization of new antigens, which are potential candidates for vaccine development. This review begins with an overview of the global status of vaccinology based on WHO data. The main part of this review describes the impact of proteomic strategies on advancements in constructing effective antibacterial, antiviral and anticancer vaccines. Diverse aspects of disease mechanisms and disease preventions have been investigated by proteomics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bacterial Infections / immunology
  • Bacterial Infections / prevention & control
  • Humans
  • Mycoses / immunology
  • Mycoses / prevention & control
  • Neoplasms / immunology
  • Neoplasms / prevention & control
  • Proteomics / methods*
  • Vaccination / methods
  • Vaccines / immunology*
  • Vaccines / pharmacology*
  • Virus Diseases / immunology
  • Virus Diseases / prevention & control

Substances

  • Vaccines